TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Concentration of linezolid in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic Glycopeptides Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic Glycopeptides Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic β-lactam-aminoglycoside Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic β-lactam-aminoglycoside Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36v Physical Function Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-36v Role Limitations Due to Physical Health Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: SF-36v Role Limitations Due to Emotional Problems Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of days missed from work due to lower back pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Decisional Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: scar-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interferon (IFN) Scores in the Transcriptome of White Blood Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline Hot Flash Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-year morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: cumulative incidence of non Q-wave myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patients' clinical status improvement using six category scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to improvement in oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exhaled acetate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exhaled propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Exhaled butyrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Limb Salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Number of Patient Differential Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Use of Diagnostic Checklist
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life SF-36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Landry's Wound Healing Index (WHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in physical activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of Phosphate Serum Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concordance of optical diagnosis with pathologic diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision in polyps sizing the pathologist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of NSF
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients With Venous Thromboembolisms
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Who Experienced Clinically Significant Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: suppression of bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic accuracy to detect ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Any Grade 3 or 4 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Muscle Toxicity or Renal Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life (QoL) score correlation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Admissions to hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Development of chronic heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Subjects With a ≥ 20% Increase in Walking Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of vaccine
Endpoint domain: Physiological/clinical
Primary endpoint: Change in Exercise-Related Neutrophil Chemotactic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Caffeine-Related Neutrophil Chemotactic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Ethanol-Related Neutrophil Chemotactic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Glucose-Related Neutrophil Chemotactic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Caffeine Plus Glucose-Related Neutrophil Chemotactic Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in State Trait Anxiety Index (STAI) State Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in State Trait Anxiety Index (STAI) Trait Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hospital Anxiety and Depression Score (HADS) - Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hospital Anxiety and Depression Score (HADS) - Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants That Tolerated the Maximum Drug Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Willingness to try local fruits and vegetables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SVR12 rate of DAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incisional surgical site infection (SSI) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of nosebleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of systemic inflammatory response syndrome (SIRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevention of surgical intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Grade of bone marrow mast cells infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of oocyte retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Systemic and local response of detected metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of circulating immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Adverse Events of Specific Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Abnormalities in Physical Examinations and Electrocardiograms (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) in High Grade Ovarian Cancer (HGOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HCV Treatment Uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lowering of the grade of the hemorroidal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain symptom differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of leakage amount of perianal fistule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Subjects Achieving a Hemagglutination Inhibition (HAI) Titer of ≥1:40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Lab results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep status
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percentage of Participants Achieving an Intact Parathyroid Hormone (iPTH) Level Within the Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in miR-21 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Balance Using the Sensory Organization Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Walking Velocity, Step Lengths, Step Widths, and Cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients who experience BTcP
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Paroxysmal Atrial Fibrillation (PAF) relapse(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of eligible participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of baseline appointments completed
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Trial acceptability qualitatively assessed through interviews with participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quick Inventory of Depression Symptomatology - Self Report (QIDS-SR) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response to Treatment, Defined as a Decrease in QIDS-SR Score by >50%
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Remission, Defined as a QIDS-SR Score <= 5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cluster of Differentiation 4 (CD4) Cell Count at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma HIV RNA Level at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Allograft Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: PFS Probability Rate at 9 Months
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Breakthrough Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph Node Yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best Overall Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hospital acquired pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal Magnetic Resonance Imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hammersmith Neonatal Neurological Examination (HNNE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: General Movement Assessment (GMs)1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 12-Item Short Form Health Survey (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Exercise self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total morphine used in the first 48 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MAO-A distribution volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence vs. absence of PN-associated cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adherence to post-polypectomy surveillance guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total effectiveness of vaccine against symptomatic influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in Vaginal health index score (VHIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline in Female sexual function index questionnaire (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in day-to-day impact of vaginal aging questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Drug and alcohol abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma LDL-Cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants reverting to normal sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of patients with a full stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Distal pulmonary SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-efficacy belief in self-care management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: miRNA profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass balance recovery of [14C]-radioactivity in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mass balance recovery of [14C]-radioactivity in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of Accurately Recalling Visual Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quit smoking rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Red Cell Transfusion Independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection rates of lung nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraindividual change of Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of patients receiving anti osteoporosis therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Concentration-time Curve of BI 730357
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological Adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal, neonatal and infant mortality
Endpoint domain: Mortality/survival
Primary endpoint: Colour stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment or Device Emergent Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient reported physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Alive at 14 days after ICU admission
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of Xeomin® in reducing glabellar rhytids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time frame from scanning to mask fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective patient feedback of mask fit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in level of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disability of the upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of risky prescribing events
Endpoint domain: Adverse events/effects
Primary endpoint: Pediatric Diabetes Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Disease Activity Score (DAS) 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage Change in Deoxyribonucleic Acid (DNA) Damage Secretory Program Induction (DDSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean sitDBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caregiver burden Index score
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Percentage of Clinical Cure (Success)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentrations (Cmax) for midostaurin and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mural thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone pharmacokinetic parameters (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone pharmacokinetic parameters (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progesterone pharmacokinetic parameters (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) based on treatment-related dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical findings in children with JIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic findings in children with JIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient history
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Lung Cathelicidin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acute Malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in antral cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in antral area after administration of prokinetic drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: feasibility of autologous ASC
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: security of autologous ASC
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: UTI incidence density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Age-related changes in fine lines on the cheek
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Age-related changes in skin elasticity on the cheek and thigh
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of toxicity and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in BEHAVE-AD psychotic symptom cluster score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in HDRS-21 scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Vaccine safety assessed by unsolicited local and systemic adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Overall fluid infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of new-onset SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With None or Mild in LCL Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline aerobic exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline ventilation during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of COVID-19 infections
Endpoint domain: Adverse events/effects